Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use (Q26747823)

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Autoradiographic localization of [3H]dextromethorphan in guinea pig brain: allosteric enhancement by ropizine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

A trial of dextromethorphan in parkinsonian patients with motor response complications

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan and dextrorphan as calcium channel antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Non-competitive N-methyl-D-aspartate antagonists protect against sound-induced seizures in DBA/2 mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effects of N-methyl-D-aspartate antagonists on the cough reflex

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Different binding affinities of NMDA receptor channel blockers in various brain regions—Indication of NMDA receptor heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Induction of phencyclidine-like behavior in rats by dextrorphan but not dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Glutamate antagonists have different effects on spontaneous locomotor activity in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan and neuromodulation: old drug coughs up new activities

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Antagonist drug selectivity for radioligand binding sites on voltage-gated and N-methyl-D-aspartate receptor-gated Ca2+ channels

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan and phencyclidine receptor ligands: Differential effects on K+- and NMDA-evoked increases in cytosolic free Ca2+ concentration

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Molecular properties of a superfamily of plasma-membrane cation channels

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Sigma-1 receptor knockout mice display a depressive-like phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Inhibition of the serotonin-induced inward current by dextromethorphan in rat nodose ganglion neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Genetic approaches for understanding the role of serotonin receptors in mood and behavior.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Pharmacologic therapy for cough

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effect of dextromethorphan on human K(v)1.3 channel activity: involvement of C-type inactivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

A 96-well filtration method for radioligand binding analysis of σ receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Sigma-1 receptor: the novel intracellular target of neuropsychotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Role of sigma-1 receptors in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Toward a more precise, clinically--informed pathophysiology of pathological laughing and crying

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma1 receptor activation in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effects of NMDA receptor antagonists on acute μ-opioid analgesia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The pharmacology of sigma-1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Sigma receptors: potential targets for a new class of antidepressant drug

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

PET radiotracers: crossing the blood-brain barrier and surviving metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The sigma-1 receptor chaperone as an inter-organelle signaling modulator

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Silencing of sigma-1 receptor induces cell death in human lens cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Characterization of functional nicotinic acetylcholine receptors involved in catecholamine release from the isolated rat adrenal gland

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Metabolism to dextrorphan is not essential for dextromethorphan's anticonvulsant activity against kainate in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Characterization of [3H]nisoxetine binding in rat vas deferens membranes: modulation by sigma and PCP ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Inhibition of the 5-HT(1A) receptor-mediated inwardly rectifying K(+) current by dextromethorphan in rat dorsal raphe neurones

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Structural determinants of the blocker binding site in glutamate and NMDA receptor channels

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Treatment of Tourette's syndrome with mecamylamine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Characterization of the functional subunit combination of nicotinic acetylcholine receptors in bovine adrenal chromaffin cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effect of preoperative oral dextromethorphan on immediate and late postoperative pain and hyperalgesia after total abdominal hysterectomy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

[3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Nicotine addiction and nicotinic receptors: lessons from genetically modified mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Inhibition of glycine currents by dextromethorphan in neurones dissociated from the guinea-pig nucleus tractus solitarii

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Antitussive activity of sigma-1 receptor agonists in the guinea-pig

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan differentially affects opioid antinociception in rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: cloning, expression, and genomic organization of receptor subunits

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Cloning and functional characterization of a sigma receptor from rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Cloning and characterization of a mouse sigma1 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Nicotine-evoked transmitter release from synaptosomes: functional association of specific presynaptic acetylcholine receptors and voltage-gated calcium channels

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Purification, molecular cloning, and expression of the mammalian sigma1-binding site

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Pathological laughter and crying: a link to the cerebellum

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

An essential component to brainstem cough gating identified in anesthetized guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Tolerability of oral dextromethorphan in patients with a history of brain ischemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan/quinidine for chorea: an open-label assessment

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Organization, control and function of extrasynaptic NMDA receptors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Role of the σ receptor in the inhibition of [3H]-noradrenaline uptake in brain synaptosomes and adrenal chromaffin cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan: cellular effects reducing neuronal hyperactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

A clinical trial of dextromethorphan in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan inhibits 5-hydroxytryptamine uptake by human blood platelets and decreases 5-hydroxyindoleacetic acid content in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effects of 2-[N-(4-Chlorophenyl)-N-methylamino]-4H-pyrido[3.2-e]-1,3-thiazin-4-one (YM928), an Orally Active α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptor Antagonist, in Models of Generalized Epileptic Seizure in Mice and Rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effect of dextrometorphan and dextrorphan on nicotine and neuronal nicotinic receptors: in vitro and in vivo selectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Spreading depression: imaging and blockade in the rat neocortical brain slice

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Behavioural phenotyping of knockout mice for the sigma-1 (σ₁) chaperone protein revealed gender-related anxiety, depressive-like and memory alterations

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Protease activated receptor 1-induced glutamate release in cultured astrocytes is mediated by Bestrophin-1 channel but not by vesicular exocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dextromethorphan for treatment of complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The role of sigma receptors in depression

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

The σ-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

L-type voltage-gated Ca2+ channels: a single molecular switch for long-term potentiation/long-term depression-like plasticity and activity-dependent metaplasticity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Dose escalation safety and tolerance study of the N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

Effect of low dose ketamine to prevent remifentanil-induced cough: a randomized, double-blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021

GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine

1 reference

https://api.crossref.org/works/10.1016%2FJ.PHARMTHERA.2016.04.010

7 January 2021